U.S. markets open in 6 hours 31 minutes

LifeSci Capital Initiates Coverage of OXiGENE

Near-term Launch of Pivotal Trial in Platinum-Recurrent Ovarian Cancer; Report Available here: http://www.lifescicapital.com/equity-research/oxigene/

NEW YORK, NY / ACCESSWIRE / March 3, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of OXiGENE (OXGN), a biopharmaceutical company developing vascular disrupting agents for patients with cancer. Lead candidate CA4P binds tubulin in endothelial cells to induce a conformational change, which restricts blood flow and starves tumors of nutrients. A pivotal Phase II/III trial with CA4P in patients with platinum-resistant ovarian cancer is expected to launch in the second quarter of 2016.

Last year OXiGENE brought in a new management team to generate value from its clinical pipeline. Dr. Bill Schwieterman took over as CEO in May 2015, Matt Loar started at CFO in July 2015, and Jeff Nelson joined the Company as VP Program Management in September 2015. This new management team is dedicated to conducting well-designed, meaningful clinical trials. After reviewing the existing data, they determined that: 1) lead candidate CA4P is best used as a combination therapy with angiogenesis inhibitors, and 2) one trial in particular, which was a randomized controlled study testing CA4P as a combination therapy, points to the activity of CA4P in ovarian cancer.

In a 29 page Initiation Report LifeSci Capital explains OXiGENE's strategy for developing vascular disrupting agents, focusing on the plan for a pivotal trial in platinum-resistant ovarian cancer.

Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on OXiGENE as developments occur.

The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.

About LifeSci Capital:

LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.

Analyst Contact:

Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com

SOURCE: LifeSci Capital, LLC